The National Health Insurance Bureau said that the new version of the medical insurance drug list wa

The biggest change in the new version of the medical insurance catalogue compared with the previous one is that the price has been reduced, and there are about 100 kinds of drugs that have been reduced in the new medical insurance catalogue, and it is cheaper for people to buy medicines.

It can be said that the new version of the medical insurance drug list launched by the National Health Insurance Bureau can have incorporated most of the drugs into it, so that our people's daily medication does not have any burden.

After the drug enters the national medical insurance drug list, it also obtains the qualification for medical insurance payment, forming the concept of "reimbursement" for the insured. Whether a drug is in the medical insurance drug list and whether it can be reimbursed greatly affects the doctor's choice of prescription and the patient's willingness to use it. Commonly used drugs for children's drugs and major diseases such as cancer, severe mental illness, hemophilia, diabetes, cardiovascular and cerebrovascular diseases have basically been included in the drug list or negotiated drug scope, effectively alleviating the clinical drug dilemma caused by the lack of adjustment of the catalog for nearly 8 years.

1. The adjustment of the new catalogue aims at the "four insistences", and strives to relieve everyone's worries about medical treatment for diseases. 2. There are new changes in the adjustment of the national medical insurance drug list this year, and the expression of appropriate preferences for special groups such as patients with rare diseases and children has attracted much attention. 3. The results of the new version of the medical insurance drug catalogue will be announced in November, focusing on the inclusion of drugs with high clinical value, high quality and reasonable medical needs.

The scope of declaration will be optimized, which can better improve the way of breeding meat, which is more convenient and safer, which is good for medical insurance.

The latest version of the National Medical Insurance Drug Catalogue announced that 111 drugs were included in the medical insurance.

The latest version of the National Medical Insurance Drug List was announced on the 18th. After adjustment, a total of 111 new drugs were added to the catalog, 3 drugs were transferred out of the catalog, and the average reduction in the number of newly approved drugs in negotiation and bidding was reached. The total number of drugs in the latest version of the National Medical Insurance Drug List has reached 2,967, including 1,586 Western medicines and 1,381 Chinese patent medicines. The number of Chinese herbal decoction pieces has not been adjusted, and there are still 892 items.

From the perspective of negotiation and bidding, 147 drugs outside the catalogue participated in the negotiation and bidding (including the renewal negotiation of drugs in the original catalogue), and 121 drugs were successfully negotiated or bidd, with an overall success rate.

The latest version of the medical insurance drug list includes drugs in the fields of anti-tumor, new crown drugs, rare diseases, etc., and drugs in the fields of chronic diseases such as diabetes and chronic obstructive pulmonary disease are also included. In terms of new crown ** medication, Azvudine tablets and Qinglung Detox Granules have successfully entered the new version of the National Medical Insurance Drug Catalog.

According to reports, this adjustment introduces the bidding mechanism, improves the renewal rules, optimizes the review process, and improves the scientific, standardized and refined level. In the adjustment, the National Health Insurance Administration firmly grasped the functional positioning of "guaranteeing the basics", took the affordability as the "bottom line", included the eligible new crown drugs in the scope of the catalog, introduced varieties with higher clinical value and cost performance, and continued to appropriately relax the payment scope of some varieties in the catalog, so as to further improve the accessibility and fairness of drugs.

Since its establishment, the National Health Insurance Administration has carried out the adjustment of the drug catalog for five consecutive years, adding a total of 618 drugs to the catalog, and at the same time transferring a number of drugs with uncertain efficacy, clinical abuse or eliminated drugs out of the catalog, leading profound changes in the use of drugs.

According to the Blue Book on the Progress and Effectiveness of China's Medical Insurance Drug Management Reform released by the Chinese Pharmaceutical Association, since 2018, the proportion of medical insurance drugs in the use of drugs in medical institutions has increased year by year, the dominant position has been further consolidated, and the rationality of clinical drug use has been actively improved. At the same time, the speed of innovative drugs entering the medical insurance has been significantly accelerated, the level of commonly used drugs has decreased significantly, and the level of drug protection for major diseases and special groups has been greatly improved, significantly reducing the drug burden of the masses.

The new version of the National Reimbursement Drug List will be officially implemented on March 1, 2023. In the next step, the National Health Insurance Administration and the Ministry of Human Resources and Social Security will pay close attention to the implementation of the new version of the catalog, improve the level of drug protection for the people, and do a good job in guiding the new coronavirus drug and protecting medical expenses.

According to the 2022 Work Plan for the Adjustment of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue, the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding. The preliminary formal review is a preliminary review of whether the declared drug meets the application conditions for the adjustment of the national medical insurance drug list and the completeness of the drug information. Through the formal review, it indicates that the drug is eligible to enter the next step of expert review.

Since its establishment in 2018, the National Health Insurance Administration has adjusted the list of medical insurance drugs for four consecutive years, including a total of 507 new drugs and good drugs, transferring 391 drugs with uncertain efficacy, and increasing the number of Western drugs and Chinese patent medicines in the current version of the medical insurance catalog to 2,860. The shortcomings of oncology drugs, chronic diseases, rare diseases and children's drugs have been gradually filled, the structure and efficacy level of drugs in the medical insurance catalogue have been greatly optimized, and the drug protection in most of the leading fields has been synchronized with the international level, and the guarantee capacity has been significantly improved. Among them, 250 drugs have been included in medical insurance through ** negotiations, many "sky-high drugs" have negotiated "civilian prices", and most drugs have obtained the lowest prices in the world, with an average price reduction of more than 50%.

In order to do a good job in the prevention and control of the new crown epidemic, the National Health Insurance Administration has previously issued regulations to temporarily include the relevant drugs in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia" into the scope of medical insurance payment, providing strong support for epidemic prevention and control. Then, if the drugs that are temporarily included in the scope of payment want to officially enter the catalog, they also need to go through the process of adjusting the drug catalog. Among the lists announced this time is the first domestic new crown oral drug Azvudine tablets.

The vast majority of drugs listed in the medical insurance list can be reimbursed regardless of whether they are inpatient or outpatient, but some drugs are restricted in use.

When the state promulgates the medical insurance catalog, it should indicate "limited payment scope" in the remarks column.

1 The drugs marked with " " in the "Remarks" column are the drugs that are paid by the basic medical insurance co-ordination ** according to the provisions when the basic medical insurance is used in the hospital, and the drugs paid by the personal account when the outpatient use is used. Work-related injury insurance and maternity insurance are not subject to this restriction.

2 The drugs marked as "limited to work-related injury insurance" in the "Remarks" column are limited to the payment of work-related injury insurance**, and do not belong to the scope of basic medical insurance and maternity insurance**.

3 The drugs marked as "limited to maternity insurance" in the "Remarks" column are limited to the payment of maternity insurance**, and do not belong to the scope of payment of basic medical insurance and work-related injury insurance**.

4. If the "Remarks" column is marked with "limited to *** and work-related injury insurance", it means that the medical expenses incurred in the case of *** can be paid by the basic medical insurance** according to the regulations, and the payment of work-related injury insurance** is not subject to this restriction.

5. The drugs marked with indications in the "Remarks" column refer to the limited scope of indications of the insured persons and have corresponding clinical signs, laboratory and auxiliary examination evidence and corresponding clinical diagnosis basis, and the expenses incurred in the use of the drug can be paid according to the regulations. This limitation is not a modification of the legal instructions of the drug, and the clinician should use the drug according to the needs of the condition and in accordance with the legal instructions of the drug.

6. Drugs marked as "limited to second-line drugs" in the "Remarks" column should be paid on the basis that the first-line drugs in the Drug Catalogue are invalid or intolerable.

Medical insurance is not only to use the drugs in the medical insurance catalog, but also to be designated pharmacies and hospitals under medical insurance.

For drugs in the medical insurance catalog, you can swipe your medical insurance card at the designated pharmacies of the medical insurance; In the outpatient clinic, you can report the co-ordinated part, and the co-ordinated part can be swiped with the medical insurance card; It can be reimbursed at the time of hospitalization (but there is generally a payment line for hospitalization).

Regardless of whether it is outpatient or inpatient, self-financed drugs still have to be paid for by yourself, and you cannot use a medical insurance card to pay for them.

It's best to ask the Civil Affairs Bureau about this.

The list of medical insurance drugs has been readjusted and will be implemented in January 2022, and the readjustment of the medical insurance catalog is also a very big change in our lives. When these expensive drugs can be included in the medical insurance, it can also reduce a lot of financial burden for us and make our lives easier.

In the past, many people lost their lives because they looked down on the disease, and the occurrence of this incident also attracted the attention of relevant personnel in our country. In this adjustment, the price of some very expensive products has been lowered on the medical insurance drugs, which also solves the problem of the masses in my country seeking medical treatment, so that everyone has no worries, and also allows everyone to have more sense of gain. In this adjustment, the drug is also to better meet the clinical needs, for example, the medication of some new crown pneumonia patients is the top priority.

Of course, it will, because now many people do not dare to go to the doctor at will after getting sick, they will feel that it costs a lot of money to seek medical treatment, so they dare not go to the doctor easily, and this phenomenon of collision and burial has also led to the increasing incidence of many people. Therefore, I also hope that everyone can know that the country is very helpful to our masses, and the country has been paying attention to the bits and pieces of our lives, in order to make changes for us, in order to make us have a better sense of life experience.

In today's society, doctors are indeed a very difficult thing for many people, because we are likely to be penniless in the process of seeing doctors. In particular, many families dare not let themselves get sick, and it costs a lot of money after getting sick, and it is also because of a problem that many families are ruined. But at this time, we don't have to worry, because with the help of the state, it has become a less difficult problem for us to see a doctor.

The updated NRDL will be implemented on January 1, 2022, as it means that more expensive drugs have officially entered the scope of medical insurance under the negotiation of the NMPA, which will greatly reduce the financial burden of patients' families in the face of expensive drugs. 1. Expand the scope and protect health

In the latest update of the medical insurance drug list, the newly included drugs fill many drug gaps. For example, the scope of tumor diseases, common diseases of women and children, chronic diseases, infectious diseases, etc., has been expanded, so that people can better enjoy economic benefits after illness. The state and each of our people stand together, and our welfare measures are directly negotiated between the state and pharmaceutical manufacturers, and our current medical insurance benefits are directly related to the efforts of the state.

2. Reduce the burden and cherish life

Tachibana I am not the God of Medicine" tells us a truth, people do not die of disease, but die of poverty. Everyone who can't afford to see a doctor or buy medicine has the biggest disease of being "poor". When medical insurance is not widely implemented, many people have lost their lives because they can't afford to see a doctor, so in order to reduce the economic burden on the people, so that everyone can afford to get sick, everyone can afford to buy medicine, and all drugs that are expensive and involve many people to use, the medical insurance bureau will come forward to organize negotiations.

3. Adapt to the change, update and iterate

The update of the medical insurance drug list means the highest demand of the people nowadays. Severe, chronic, hereditary Tung Roundness Disease is commonly known as a rare disease, also known as "orphan disease", which has a very low probability of occurrence and is extremely rare on the market. With the update of the medical insurance catalog, 7 drugs for rare diseases have been included in the catalog, giving these rare disease patients more hope.

If a new type of drug appears on the market, the Health Insurance Bureau will include it in the negotiation as needed, and once successful, it can provide everyone with welfare. <>

Medical insurance is the biggest backing guarantee for our people's livelihood, so that our people have a lot less worries about seeing a doctor.

Of course there have been changes. It will make our lives easier, it will also reduce the cost of living, and it will make it easier to see a doctor.

It will make a big change in life, and it will also make many people get a good feeling in their lives, because many ** have been downgraded.

A few days ago, the National Healthcare Security Administration issued an announcement on the phased results of the expert review of the declared drugs that have passed the formal review for the adjustment of the National Medical Insurance Drug List in 2022

In accordance with the "2022 Work Plan for the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance", the National Health Insurance Administration organized experts to conduct a comprehensive review of the declared drugs that passed the adjustment form review of the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue in 2022 (hereinafter referred to as the 2022 National Medical Insurance Drug Catalogue). At present, the expert review work has ended, and the announcement is as follows:

1. Each applicant enterprise can log on to the National Medical Insurance Service Platform (National Medical Insurance Drug Catalogue Adjustment Declaration" module (hereinafter referred to as the application module) to inquire about the expert review results.

2. For drugs whose evaluation results are "new to be negotiated", "new to be added to bidding", "to be negotiated for renewal" and "to be simply renewed", the corresponding enterprise will be in the "declaration module"** corresponding to the "confirmation letter template". Please fill in and affix the official seal as required and upload it to the "Declaration Module" before 17:00 on October 20, 2022, and send the original to the National Health Insurance Administration (subject to the postmark).

3. To confirm the participation in the negotiation and the drugs to participate in the bidding, the corresponding enterprise shall fill in and submit the corresponding "submission material template" in the "declaration module". Enterprises should ensure that the relevant data and materials submitted are complete, authentic and reliable, and send one copy of the paper version and one electronic version of the CD (the first volume of materials is provided in word and pdf version) to the National Health Insurance Administration before 17:00 on November 3, 2022 (subject to the postmark).

Please click "Details" in the "Negotiation Bidding Information" column to view the contents of the negotiation bidding reference drugs, negotiation main specifications and medical insurance payment scope determined by expert review.

4. If the evaluation result is "new to be negotiated" or "new to be added by bidding", it means that the drug has been included in the negotiation and bidding scope of the 2022 National Medical Insurance Drug Catalogue and has obtained the qualification for negotiation and bidding, which does not mean that the drug has been included in the 2022 National Medical Insurance Qinxingchai Drug Catalogue.

5. In order to ensure the smooth progress of the subsequent stage of the catalogue adjustment, before the official release of the 2022 National Medical Insurance Drug Catalogue, all applicant enterprises should not release any information about this adjustment.